Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Fears Report-Writing Burden From Supply Chain Risk Guidance US FDA Is Drafting

Executive Summary

As agency prepares guidance on CARES Act requirement for risk management plans to help prevent shortages of critical medicines, industry raised concerns that a broad interpretation of the “life-saving drugs” term used in the legislation could make compliance challenging.

You may also be interested in...



Reshoring Debate Continues As COVID-19 Drives New Wave Of US Drug Shortages

As the response to another wave of COVID-19 infections continues, fill rates of critical medicines such as methylprednisolone are dropping. But experts say the answer is not to concentrate manufacturing in US facilities, which could lead to further risks if US supply is disrupted.

How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention

Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.

ICH Q9 Revision Delayed By Three Months Due To COVID; Focus Spans Risk Assessments, Shortages

Extension will add training materials with goal of reducing quality defects and recalls. Revision process will also address shortage indicators related to production failures in an attempt to head off drug shortages.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel